Nautilus Biotechnology Inc reports results for the quarter ended December 31 - Earnings Summary

Nautilus Biotechnology

27/02/2025 16:32

Nautilus Biotechnology Inc NAUT.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended December 31, identical to the same quarter last year.  The mean expectation of five analysts for the quarter was for a loss of 16 cents per share. Wall Street expected results to range from -18 cents to -15 cents per share.

Reported revenue was zero​; analysts expected zero.

Nautilus Biotechnology Inc's reported EPS for the quarter was a loss of 14 cents​.

The company reported a quarterly loss of $17.59 million.

Nautilus Biotechnology Inc shares had fallen by 14.9% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $3.00

This summary was machine generated from LSEG data February 27 at 04:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.16
-0.14
Beat
Sep. 30 2024
-0.16
-0.13
Beat
Jun. 30 2024
-0.16
-0.14
Beat
Mar. 31 2024
-0.16
-0.15
Beat